Emyria (formerly Emerald Clinics) and Zelira Therapeutics have inked a deal to collect data from Emyria patients using Zelira’s cannabinoid-based Zenivol medicine to treat insomnia.
Under the arrangement, de-identified patient data including diagnosis, co-morbidities, concomitant medications, dosage and responses to Zenivol will be assessed using clinical and subjective endpoints including the Insomnia Severity Index (ISI) questionnaire.
Zelira will pay Emyria an upfront fee of A$50,000 along with a subscription fee for each patient enrolled in the study, up to a maximum of 100 participants. The term of the agreement is for 12 months with an option to extend the subscription fees on an ongoing basis.
Zelira managing director Richard Hopkins said: “Australia’s commitment to developing a highly regulated market for prescription cannabis medicines means this country is a global leader in collection of high-quality real-world data relating to patients treated with medicinal cannabis.
“Being able to access real-world data, in real-time, from patients treated with Zenivol will have immediate benefit for our go-to-market strategy.
“This information will also inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to regulatory approval.”